Literature DB >> 21907407

Meta-analysis for the potential application of FLT3-TKD mutations as prognostic indicator in non-promyelocytic AML.

Wei Li1, Li Zhang, Liang Huang, Yingchang Mi, Jianxiang Wang.   

Abstract

A meta-analysis was performed to demonstrate the prognostic significance of FLT3-TKD mutations in acute myeloid leukemia (AML). The overall hazard ratio (HR) of FLT3-TKD/FLT3-wild type (WT) for disease-free survival (DFS) was 1.20. The overall HRs for overall survival (OS) of FLT3-TKD to FLT3-ITD and FLT3-WT were 0.87 and 1.18. For non-promyelocytic AML with intermediate cytogenetics, the overall HR for DFS of FLT3-TKD/FLT3-ITD was 0.71. The HR for OS of FLT3-TKD/FLT3-ITD was 0.75. Adult AML patients with FLT3-TKD mutations exhibit better outcomes than those with FLT3-ITD. The patients with FLT3-TKD mutations with intermediate cytogenetics had similar OS as those with FLT-WT mutations.
Copyright © 2011 Elsevier Ltd. All rights reserved.

Entities:  

Mesh：

Substances：

Year:  2011        PMID： 21907407     DOI： 10.1016/j.leukres.2011.08.014

Source DB:  PubMed          Journal:  Leuk Res        ISSN： 0145-2126            Impact factor:   3.156


  6 in total

Review 1.  Frontline treatment of acute myeloid leukemia in adults.

Authors:  Gevorg Tamamyan; Tapan Kadia; Farhad Ravandi; Gautam Borthakur; Jorge Cortes; Elias Jabbour; Naval Daver; Maro Ohanian; Hagop Kantarjian; Marina Konopleva
Journal:  Crit Rev Oncol Hematol       Date:  2016-12-11       Impact factor: 6.312

Review 2.  Which FLT3 Inhibitor for Treatment of AML?

Authors:  Jayastu Senapati; Tapan Mahendra Kadia
Journal:  Curr Treat Options Oncol       Date:  2022-03-08

3.  Absence of FLT3 mutations in Iranian adult T-cell leukemia/lymphoma patients.

Authors:  Hossein Ayatollahi; Mohammadhadi Sadeghian; Mohammadmahdi Kooshyar; Abass Shirdel; Hossein Rahimi; Amirhossein Jafarian; Saeide Ghazaei; Narges Soltani; Fatemeh Shams; Neda Motamedi Rad; Sepideh Shakeri
Journal:  Med J Islam Repub Iran       Date:  2018-06-09

4.  Clinical resistance to crenolanib in acute myeloid leukemia due to diverse molecular mechanisms.

Authors:  Haijiao Zhang; Samantha Savage; Anna Reister Schultz; Daniel Bottomly; Libbey White; Erik Segerdell; Beth Wilmot; Shannon K McWeeney; Christopher A Eide; Tamilla Nechiporuk; Amy Carlos; Rachel Henson; Chenwei Lin; Robert Searles; Hoang Ho; Yee Ling Lam; Richard Sweat; Courtney Follit; Vinay Jain; Evan Lind; Gautam Borthakur; Guillermo Garcia-Manero; Farhad Ravandi; Hagop M Kantarjian; Jorge Cortes; Robert Collins; Daelynn R Buelow; Sharyn D Baker; Brian J Druker; Jeffrey W Tyner
Journal:  Nat Commun       Date:  2019-01-16       Impact factor: 17.694

5.  Frequency and Prognostic Relevance of FLT3 Mutations in Saudi Acute Myeloid Leukemia Patients.

Authors:  Ghaleb Elyamany; Mohammad Awad; Kamal Fadalla; Mohamed Albalawi; Mohammad Al Shahrani; Abdulaziz Al Abdulaaly
Journal:  Adv Hematol       Date:  2014-02-20

Review 6.  The Impact of Flt3 Gene Mutations in Acute Promyelocytic Leukemia: A Meta-Analysis.

Authors:  Gledson L Picharski; Diancarlos P Andrade; Ana Luiza M R Fabro; Luana Lenzi; Fernanda S Tonin; Raul C Ribeiro; Bonald C Figueiredo
Journal:  Cancers (Basel)       Date:  2019-09-05       Impact factor: 6.639
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.